Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antispasmodic agent.
## Primary Indications
* Symptomatic relief of abdominal pain and cramps associated with gastrointestinal disorders.
* Management of primary dysmenorrhea.
## Adult Dosing
* **Mefenamic acid:** 250 mg to 500 mg orally every 6 to 8 hours as needed, not to exceed 1500 mg daily.
* **Hyoscine butylbromide:** 10 mg to 20 mg orally three times daily.
* The specific dose of the combination product will depend on the formulation available.
## Pediatric Dosing
* **Mefenamic acid:** Generally not recommended for children under 12 years of age due to limited data. If used, typical dosing is 5-10 mg/kg orally every 6-8 hours, not to exceed 4 doses in 24 hours or the adult maximum.
* **Hyoscine butylbromide:** Data for pediatric use is limited. Use with caution and at the discretion of the prescriber.
## Dose Adjustments
* **Renal Impairment:** Use with caution; reduced doses may be considered for mefenamic acid component, especially in severe impairment. Monitor for signs of renal toxicity.
* **Hepatic Impairment:** Use with caution; consider reduced doses for mefenamic acid component. Monitor liver function.
* **Elderly:** Increased risk of adverse effects, particularly gastrointestinal bleeding and renal toxicity with the mefenamic acid component. Use with caution and at the lowest effective dose.
## Contraindications
* Hypersensitivity to mefenamic acid, hyoscine butylbromide, or any component of the formulation.
* History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs.
* Active gastrointestinal ulceration or bleeding.
* Severe renal impairment.
* Severe hepatic impairment.
* Severe heart failure.
* Conditions where increased heart rate is undesirable (e.g., thyrotoxicosis, tachycardia, prostatic hypertrophy, glaucoma).
* Myasthenia gravis.
* Ileus, paralytic ileus.
* Megaloblastic anemia.
## Adverse Effects
* **Mefenamic acid:** Dyspepsia, nausea, vomiting, abdominal pain, diarrhea, constipation, dizziness, headache, rash. Serious risks include gastrointestinal bleeding, ulceration, perforation, renal toxicity, hepatic impairment, cardiovascular events.
* **Hyoscine butylbromide:** Dry mouth, blurred vision, urinary retention, constipation, tachycardia, drowsiness.
## Key Drug Interactions
* **Mefenamic acid:**
* Anticoagulants (e.g., warfarin): Increased risk of bleeding.
* Corticosteroids: Increased risk of GI ulceration and bleeding.
* Other NSAIDs, aspirin: Increased risk of GI toxicity and bleeding.
* Diuretics, ACE inhibitors, ARBs: Reduced antihypertensive effect and increased risk of renal impairment.
* Lithium: Increased serum lithium levels.
* Methotrexate: Increased methotrexate toxicity.
* **Hyoscine butylbromide:**
* Anticholinergics: Potentiated anticholinergic effects.
* Opioid analgesics: Increased risk of paralytic ileus.
* Amantadine: Increased anticholinergic adverse effects.
* Tricyclic antidepressants, MAO inhibitors: May potentiate anticholinergic effects.
## Monitoring
* **Mefenamic acid component:** Monitor for signs of gastrointestinal bleeding (melena, hematemesis), renal function (BUN, creatinine), liver function (LFTs), and blood pressure.
* **Hyoscine butylbromide component:** Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention).
## Clinical Pearls
* Administer with food or milk to minimize gastrointestinal upset from mefenamic acid.
* Limit duration of use to the shortest effective period.
* Avoid concomitant use with other NSAIDs.
* Be aware of the potential for delayed diagnosis of appendicitis if used for abdominal pain.
***
*Disclaimer: This information is intended for clinical use and does not replace professional judgment. Always consult the most current prescribing information and relevant guidelines for definitive patient care decisions.*
